Posted by ed_uk on August 28, 2006, at 6:25:28
Licensing application submitted to FDA for extended release guanfacine (Connexyn) for ADHD
Shire plc has submitted a new drug application to the FDA for its investigational drug guanfacine extended release (SPD503, Connexyn™), which, if approved, would be the first once-daily selective alpha-2A-adrenoceptor agonist for the treatment of ADHD in children aged 6 to 17 years. Guanfacine is not a CNS stimulant or a controlled substance and is claimed to have no known potential for abuse or dependence.
poster:ed_uk
thread:680766
URL: http://www.dr-bob.org/babble/20060825/msgs/680766.html